Literature DB >> 14615374

Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen AalphaIVS4 + 1G>T mutation and an AalphaGln328 truncation (fibrinogen Keokuk).

Phil Lefebvre1, Pauline T Velasco, Amy Dear, Karim C Lounes, Susan T Lord, Stephen O Brennan, David Green, Laszlo Lorand.   

Abstract

Two siblings with hypofibrinogenemia have lifelong trauma-related bleeding. Recently, the brother experienced recurrent thrombosis after cryoprecipitate infusions following surgery. The sister had 6 miscarriages. Plasma clots in each were resistant to compression and fibrinolysis and were soluble in 5 M urea. Examination by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) revealed only the presence of crosslinked gamma-gamma fibrin chain dimers without high polymers of alpha n. Fibrin clots contained an abnormal 35-kDa constituent recognized by an antibody to the mature fibrinogen Aalpha-chain residues 241-476 but not by antibodies to Aalpha219-348 or Aalpha349-406. DNA analysis revealed a heterozygous CAA-->TAA mutation at the codon for amino acid 328 of the Aalpha gene in these siblings and 2 asymptomatic family members. The Gln328stop mutation (fibrinogen Keokuk) predicted a 46% truncation and the production of a 35-kDa Aalpha chain. Analysis of purified fibrinogen revealed expression of the abnormal Aalpha chain in 4 family members but found no normal fibrinogen in the 2 hypofibrinogenemic patients. This paradox was resolved when they and their asymptomatic mother were found to be heterozygous for a second Aalpha mutation, a GT-->TT splice site mutation in intron 4 (IVS4 + 1 G> T). However, compound heterozygosity for both mutations was required for the expression of severe hypodysfibrinogenemia and for clinical symptoms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14615374     DOI: 10.1182/blood-2003-07-2316

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Hypodysfibrinogenemia causing mild bleeding and thrombotic complications in a compound heterozygote of AalphaIVS4+1G>T mutation and Aalpha4841delC truncation (Aalpha(Perth)).

Authors:  Asier Jayo; Erin Arnold; Consuelo González-Manchón; David Green; Susan T Lord
Journal:  Thromb Haemost       Date:  2009-04       Impact factor: 5.249

Review 2.  Thrombosis in Inherited Fibrinogen Disorders.

Authors:  Wolfgang Korte; Man-Chiu Poon; Alfonso Iorio; Michael Makris
Journal:  Transfus Med Hemother       Date:  2017-03-14       Impact factor: 3.747

3.  Hypofibrinogenemia with preserved hemostasis and protection from thrombosis in mice with an Fga truncation mutation.

Authors:  Woosuk S Hur; David S Paul; Emma G Bouck; Oscar A Negrón; Jean-Marie Mwiza; Lauren G Poole; Holly M Cline-Fedewa; Emily G Clark; Lih Jiin Juang; Jerry Leung; Christian J Kastrup; Tatiana P Ugarova; Alisa S Wolberg; James P Luyendyk; Wolfgang Bergmeier; Matthew J Flick
Journal:  Blood       Date:  2022-03-03       Impact factor: 22.113

4.  Ranking reactive glutamines in the fibrinogen αC region that are targeted by blood coagulant factor XIII.

Authors:  Kelly Njine Mouapi; Jacob D Bell; Kerrie A Smith; Robert A S Ariëns; Helen Philippou; Muriel C Maurer
Journal:  Blood       Date:  2016-03-07       Impact factor: 22.113

5.  Deletion of five residues from the coiled coil of fibrinogen (Bbeta Asn167_Glu171del) associated with bleeding and hypodysfibrinogenemia.

Authors:  Stephen O Brennan; Ryan L Davis; Robin Lowen; Anna Ruskova
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

Review 6.  Fibrinogen αC domain: Its importance in physiopathology.

Authors:  Jeannette Soria; Shahsoltan Mirshahi; Sam Qiumars Mirshahi; Remi Varin; Linda L Pritchard; Claudine Soria; Massoud Mirshahi
Journal:  Res Pract Thromb Haemost       Date:  2019-02-15

Review 7.  Extension of the Human Fibrinogen Database with Detailed Clinical Information-The αC-Connector Segment.

Authors:  Zofie Sovova; Klara Pecankova; Pavel Majek; Jiri Suttnar
Journal:  Int J Mol Sci       Date:  2021-12-23       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.